Search

Search bills, members, committees and pages...

HB 1199

Louisiana HousePassed

Summary

HB 1199, which provides relative to health insurance coverage for genetic testing and the treatment of SCN2A-associated medical conditions (EN NO IMPACT See Note), was introduced in the House on Mar 31, 2026 by Rep. Edmond Jordan (D) with 6 co-sponsors. It last saw action on Jun 9, 2026: Effective date: 06/09/2026.


Record

Text

HB 1199 has 6 co-sponsors and 3 roll calls.

hb1199/chaptered.txt
ENROLLED
2026 Regular Session
ACT No. 884
HOUSE BILL NO. 1199
BY REPRESENTATIVES JORDAN, CHASSION, AND LACOMBE AND SENATORS
CARTER, EDMONDS, TALBOT, AND WHEAT
AN ACT
To enact R.S. 22:1049.1, relative to health insurance; to require coverage for genetic testing
for SCN2A associated disorders; to require coverage for medically necessary
treatment of SCN2A associated medical conditions; to provide for definitions; to
provide for medical necessity determinations; to provide for coverage standards; to
provide for prior authorization and cost-sharing requirements; to provide for
effectiveness; and to provide for related matters.
Be it enacted by the Legislature of Louisiana:
Section 1. R.S. 22:1049.1 is hereby enacted to read as follows:
§1049.1. Requirements for coverage for genetic testing and treatment of
SCN2A-associated medical conditions
A. For the purpose of this Section, the following terms have the meanings
ascribed to them:
(1) "Genetic testing" means a laboratory method used to detect changes in
genes, gene expression, or chromosomes in a person's cells or tissues. Genetic
testing may be done to look for inherited changes in a person's genes that may be a
sign that the person has an increased risk of developing a specific disease or
condition or of having a child or other family member that is covered under the
enrollee's policy with the disease or condition.
(2) "Health coverage plan" means any hospital, health, or medical expense
insurance policy, hospital or medical service contract, employee welfare benefit plan,
contract or agreement with a health maintenance organization or a preferred provider
organization, health and accident insurance policy, or any other insurance contract
of this type, including a group insurance plan and the Office of Group Benefits
programs.
Page 1 of 3
CODING: Words in struck through type are deletions from existing law; words underscored
are additions.
HB NO. 1199 ENROLLED
(3) "Medically necessary treatment" means health services necessary for the
diagnosis, treatment, cure, or alleviation of health conditions, illnesses, injuries, or
diseases. These services must be necessary and appropriate to address the specific
health issue or its associated symptoms, and must adhere to the generally accepted
standards of medical care within the community.
(4) "SCN2A" refers to a gene located on chromosome 2, which provides
critical instructions for the synthesis of a sodium channel protein essential for
neurotransmission in the brain. The SCN2A gene encodes a voltage-gated sodium
channel that plays a pivotal role in the generation of neuronal action potentials.
Pathogenic variants of the SCN2A gene are associated with a wide spectrum of
neurodevelopmental disorders, which may include but are not limited to neonatal or
infantile onset epilepsy, developmental delay, autism spectrum disorder, intellectual
disability, and movement disorders.
B. Any health coverage plan delivered, issued for delivery, renewed, or
otherwise contracted for in this state on or after January 1, 2027, shall provide
coverage for genetic testing to diagnose SCN2A-associated medical conditions when
ordered by a treating physician or advanced practice provider and determined to be
medically necessary by the health coverage plan.
C. A health coverage plan shall provide coverage for medically necessary
treatment of SCN2A-associated medical conditions, including but not limited to:
(1) Anti-seizure medications and other pharmacologic therapies.
(2) Rehabilitative and habilitative services, including physical, occupational,
speech, and behavioral therapies.
(3) Medically necessary durable medical equipment, assistive technology,
and adaptive devices.
(4) Nutritional, feeding, and gastrointestinal management services.
(5) Any additional treatment determined to be medically necessary by the
treating physician or advanced practice provider.
D. Medical necessity shall be determined by the enrollee's treating physician
or advanced practice provider. Any denial of coverage based on medical necessity
Page 2 of 3
CODING: Words in struck through type are deletions from existing law; words underscored
are additions.
HB NO. 1199 ENROLLED
shall be in writing and shall include the reasons for denial and an explanation of how
the request does not meet medical necessity standards. Denials may be appealed
pursuant to R.S. 22:1121 et seq.
E. A health coverage plan may require prior authorization for services
covered under this Section if such procedures are applied in a nondiscriminatory
manner and are no more restrictive than those applied to other benefits.
F. A health coverage plan may impose copayments, deductibles, or
coinsurance amounts on benefits required by this Section. Such cost-sharing shall
not be greater than that applied to other medical or surgical benefits under the plan.
G. A health coverage plan shall not deny coverage for genetic testing or
medically necessary treatment under this Section on the basis of disability,
developmental status, or preexisting condition.
H. Benefits required by this Section shall be considered rehabilitative or
habilitative services and devices for purposes of any state or federal requirement for
coverage of essential health benefits.
I. The provisions of this Section do not apply to limited benefit health
insurance policies or contracts.
Section 2. This Act shall become effective upon signature by the governor or, if not
signed by the governor, upon expiration of the time for bills to become law without signature
by the governor, as provided by Article III, Section 18 of the Constitution of Louisiana. If
vetoed by the governor and subsequently approved by the legislature, this Act shall become
effective on the day following such approval.
SPEAKER OF THE HOUSE OF REPRESENTATIVES
PRESIDENT OF THE SENATE
GOVERNOR OF THE STATE OF LOUISIANA
APPROVED:
Page 3 of 3
CODING: Words in struck through type are deletions from existing law; words underscored
are additions.

Provides relative to health insurance coverage for genetic testing and the treatment of SCN2A-associated medical conditions (EN NO IMPACT See Note)

Sponsors

Rep. Edmond Jordan (D) sponsors HB 1199, and 6 members have co-sponsored it.

Committees

HB 1199 went before 3 committees: Insurance, Appropriations and Judiciary B.

Insurance
Insurance
Referred to · Apr 1, 2026 · 44 Bills
Appropriations
Appropriations
Referred to · Apr 27, 2026 · 45 Bills
Judiciary B
Judiciary B
Referred to · May 21, 2026

History

HB 1199 has taken 23 actions since Mar 31, 2026, the latest on Jun 9, 2026.

ChamberAction
Jun 9, 2026
House
Signed by the Governor. Becomes Act No. 884.
Jun 9, 2026
House
Effective date: 06/09/2026.
Jun 4, 2026
House
Sent to the Governor for executive approval.
Jun 1, 2026
Senate
Signed by the President of the Senate.
May 31, 2026
House
Enrolled and signed by the Speaker of the House.

Votes

HB 1199 went to 3 roll calls across both chambers, the latest on May 29, 2026 at 960.

ChamberQuestion
Yea
Nay
May 29, 2026
House
House Vote on HB 1199 CONCUR IN SENATE AMENDMENTS (#1753)
96
0
May 28, 2026
Senate
Senate Vote on HB 1199 FINAL PASSAGE (#1502)
32
0
May 20, 2026
House
House Vote on HB 1199 FINAL PASSAGE (#1451)
94
0

Source: legis.la.gov · legiscan.com